Incidence of Japanese Encephalitis and Acute Encephalitis Syndrome Hospitalizations in the Medium-Endemic Region in Central India.
Central India
Hospitalization rates
Impact assessment
Incidence estimates
Infectious encephalitis
Japanese encephalitis
Journal
Journal of epidemiology and global health
ISSN: 2210-6014
Titre abrégé: J Epidemiol Glob Health
Pays: Switzerland
ID NLM: 101592084
Informations de publication
Date de publication:
Jun 2023
Jun 2023
Historique:
received:
19
02
2023
accepted:
17
04
2023
medline:
19
6
2023
pubmed:
10
5
2023
entrez:
10
5
2023
Statut:
ppublish
Résumé
We estimated the incidence of Japanese encephalitis (JE) and acute encephalitis syndrome (AES) following routine immunization with the live-attenuated SA 14-14-2 JE vaccine. We implemented enhanced surveillance of AES and JE hospitalizations in endemic districts in Maharashtra and Telangana States during 2015-2016 and 2018-2020. We estimated incidence and compared differences in the incidence of JE and AES between two states, and vaccinated and unvaccinated districts during two study periods. We also considered secondary data from public health services to understand long-term trends from 2007 to 2020. The annual AES incidence rate of 2.25 cases per 100,000 children in Maharashtra during 2018-2020 was significantly lower than 3.36 cases per 100,000 children during 2015-2016. The six JE-vaccinated districts in Maharashtra had significantly lower incidence rates during 2018-2020 (2.03, 95% CI 1.73-2.37) than in 2015-16 (3.26, 2.86-3.70). In addition, the incidence of both JE and AES in two unvaccinated districts was higher than in the vaccinated districts in Maharashtra. Telangana had a lower incidence of both JE and AES than Maharashtra. The AES incidence rate of 0.95 (0.77-1.17) during 2018-2020 in Telangana was significantly lower than 1.67 (1.41-1.97) during 2015-2016. The annual incidence rate of Japanese encephalitis was < 1 case per 100,000 children. It indicated accelerated control of Japanese encephalitis after routine immunization. However, the annual incidence of acute encephalitis syndrome was still > 1 case per 100,000 children. It highlights the need for improving surveillance and evaluating the impacts of vaccination.
Sections du résumé
BACKGROUND
BACKGROUND
We estimated the incidence of Japanese encephalitis (JE) and acute encephalitis syndrome (AES) following routine immunization with the live-attenuated SA 14-14-2 JE vaccine.
METHODS
METHODS
We implemented enhanced surveillance of AES and JE hospitalizations in endemic districts in Maharashtra and Telangana States during 2015-2016 and 2018-2020. We estimated incidence and compared differences in the incidence of JE and AES between two states, and vaccinated and unvaccinated districts during two study periods. We also considered secondary data from public health services to understand long-term trends from 2007 to 2020.
RESULTS
RESULTS
The annual AES incidence rate of 2.25 cases per 100,000 children in Maharashtra during 2018-2020 was significantly lower than 3.36 cases per 100,000 children during 2015-2016. The six JE-vaccinated districts in Maharashtra had significantly lower incidence rates during 2018-2020 (2.03, 95% CI 1.73-2.37) than in 2015-16 (3.26, 2.86-3.70). In addition, the incidence of both JE and AES in two unvaccinated districts was higher than in the vaccinated districts in Maharashtra. Telangana had a lower incidence of both JE and AES than Maharashtra. The AES incidence rate of 0.95 (0.77-1.17) during 2018-2020 in Telangana was significantly lower than 1.67 (1.41-1.97) during 2015-2016.
CONCLUSIONS
CONCLUSIONS
The annual incidence rate of Japanese encephalitis was < 1 case per 100,000 children. It indicated accelerated control of Japanese encephalitis after routine immunization. However, the annual incidence of acute encephalitis syndrome was still > 1 case per 100,000 children. It highlights the need for improving surveillance and evaluating the impacts of vaccination.
Identifiants
pubmed: 37162636
doi: 10.1007/s44197-023-00110-7
pii: 10.1007/s44197-023-00110-7
pmc: PMC10271976
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
173-179Subventions
Organisme : Indian Council of Medical Research (ICMR), New Delhi (INDIA)
ID : ICMR/VIR/2/2018/ECD-I
Informations de copyright
© 2023. The Author(s).
Références
Indian J Med Res. 2010 Oct;132:395-9
pubmed: 20966517
J Infect. 2014 Aug;69(2):200-2
pubmed: 24657663
Int J Infect Dis. 2019 Jul;84S:S19-S24
pubmed: 30641206
Vaccine. 2021 Aug 16;39(35):4973-4978
pubmed: 34325931
J Clin Virol. 2021 Nov;144:104970
pubmed: 34560339
J Clin Virol. 2022 Aug;153:105194
pubmed: 35687988
Indian Pediatr. 2015 Oct;52(10):837-9
pubmed: 26499003
Biomed Res Int. 2013;2013:896749
pubmed: 24319693
Bull World Health Organ. 2011 Oct 1;89(10):766-74, 774A-774E
pubmed: 22084515
Natl Med J India. 2017 Nov-Dec;30(6):317-320
pubmed: 30117441
Open Virol J. 2018 Aug 31;12:121-130
pubmed: 30288200
Emerg Infect Dis. 2013;19(9):1361-7
pubmed: 23965505
J Med Virol. 2008 Jan;80(1):118-24
pubmed: 18041027
Indian J Community Med. 2012 Oct;37(4):240-51
pubmed: 23293439